The Unmet Medical Needs of Current Injectable Antidiabetic Therapies in China: Patient and Health Care Professional Perspectives
Author:
Funder
Lilly Suzhou Pharmaceutical Co. Ltd.
National Key R&D Program: Multi-factorial Integrative Management of Type 2 Diabetes
Publisher
Elsevier BV
Subject
Pharmacology (medical),Pharmacology
Reference49 articles.
1. Diabetes and its drivers: the largest epidemic in human history?;Zimmet;Clin Diabetes Endocrinol,2017
2. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications;Zheng;Nat Rev Endocrinol,2018
3. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study;Bommer;Lancet Diabetes Endocrinol,2017
4. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013;Wang;JAMA,2017
5. Economic burden in Chinese patients with diabetes mellitus using electronic insurance claims data;Huang;PLoS One,2016
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Treatment-Related Attributes of Diabetes Therapies and How People with Type 2 Diabetes Report Their Impact on Indicators of Medication-Taking Behaviors;Patient Preference and Adherence;2022-08
2. Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States;Clinical Therapeutics;2022-06
3. The prevalence and evidence-based management of needle fear in adults with chronic disease: A scoping review;PLOS ONE;2021-06-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3